Guías clínicas para el tratamiento de la rosácea

  • Ana Lucía Molina
  • Ángela Londoño
  • Sara María Escobar
  • Marcela Benítez

Resumen

La rosácea es una condición inflamatoria crónica que afecta la piel y los ojos, caracterizada por eritema transitorio o persistente, pápulas y pústulas, y cuando está en etapas avanzadas, se presenta con “fimatosis”. Existen múltiples modalidades terapéuticas para esta entidad, pero es poco claro cuál es la más efectiva.

Objetivo. Recolectar y analizar los diferentes estudios que hay en la literatura científica sobre el tratamiento de la rosácea y dar recomendaciones clínicas basadas en el nivel de evidencia.

Métodos. La búsqueda de artículos sobre las diferentes modalidades de tratamiento de la rosácea pápulo-pustular, eritemato-telangiectásica y “fimatosa”, se hizo en las bases de datos Embase, Medline, Lilacs, Ovid, con el buscador Pubmed, desde enero de 1980 hasta junio de 2011. Luego de recolectar la literatura científica disponible, se analizó la información y se calificó la calidad de los estudios utilizando las escalas de Jadad para ensayos clínicos de asignación aleatoria, y CASPE para estudios de casos y controles, cohortes y estudios cualitativos. Finalmente, se dan recomendaciones clínicas según el grado de evidencia encontrado.

Resultados. Se encontraron 178 artículos de las diferentes modalidades terapéuticas. En la rosácea pápulo-pustular los tratamientos con mayor nivel de evidencia son el metronidazol, el ácido azelaico, la sulfacetamida y la doxiciclina; en la rosácea eritemato-telangiectásica, las modalidades más utilizadas son los medios físicos, y en la rosácea “fimatosa”, el tratamiento de primera línea es el láser de CO2 .

Conclusiones. Este documento presenta una revisión actualizada de la literatura científica y formula recomendaciones terapéuticas basadas en el mejor nivel de evidencia que se encontró. Su implementación permitirá la unificación de criterios, con el objetivo de ofrecer un mejor tratamiento a los pacientes con la enfermedad.

Biografía del autor/a

Ana Lucía Molina

Médica, residente de III año de Dermatología, Facultad de Medicina, Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana, Medellín, Colombia

Ángela Londoño

Médica, dermatóloga y epidemióloga; docente, Facultad de Medicina, Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana, Medellín, Colombia

Sara María Escobar

Estudiante de internado, Facultad de Medicina, Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana, Medellín, Colombia

Marcela Benítez

Estudiante de internado, Facultad de Medicina, Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana, Medellín, Colombia

Referencias bibliográficas

1. van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J Am Acad Dermatol. 2007;56:107-15.

2. Elewski B, Draelos Z, Dréno B, Jansen T, Layton A, Picardo M. Rosacea - global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25:188-200.

3. Powell FC. Rosacea. N Engl J Med. 2005;352:793-803.

4. Bamford JT. Rosacea: Current thoughts on origin. Semin Cutan Med Surg. 2001;20:199-206.

5. Zuber TJ. Rosacea. Prim Care. 2000;27:309-18.

6. Gallo R, Drago F, Paolino S, Parodi A. Rosacea treatments: What’s new and what’s on the horizon? Am J Clin Dermatol. 2010;11:299-303.

7. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-41.

8. Wilkin J. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-7.

9. Wilkin J. Standard grading system for rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-12.

10. Pereira TM, Vieira AP, Basto AS. Rosacea with extensive extrafacial lesions. Int J Dermatol. 2008;47:52-5.

11. AGREE Next Steps Consortium. Appraisal of guidelinesfor research & evaluation II. Ontario: Agree; 2009. Fecha de consulta: 3 de mayo de 2012. Disponible en: http://www.agreetrust.org .

12. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: A double-blind clinical trial. J Am Acad Dermatol. 1998;39:502-4.

13. Dahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45:723-30.

14. Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br J Dermatol. 1983;108:327-32.

15. Dahl MV, Katz HI, Krueger GG, Millikan LE, Odom RB, Parker F, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-83.

16. Tan JKL, Girard C, Krol A, Murray HE, Papp KA, Poulin Y, et al. Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. J Cutan Med Surg. 2002;6:529-34.

17. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol. 1987;123:609-14.

18. Barnhorst DA Jr, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology. 1996;103:1880-3.

19. Aronson IK, Rumsfield JA, West DP, Alexander J, Fischer JH, Paloucek FP. Evaluation of topical metronidazole gel in acne rosacea. Drug Intell Clin Pharm. 1987;21:346-51.

20. Breneman DL, Stewart D, Hevia O, Hino PD, Drake LA. A doubleblind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis. 1998;61:44-7.

21. Wolf JE Jr, Del Rosso JQ. The CLEAR trial: Results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79:73-80.

22. Draelos ZD. Assessment of skin barrier function in rosacea patients with a novel 1% metronidazole gel. J Drugs Dermatol. 2005;4:557-62.

23. Eriksson G, Nord CE. Impact of topical metronidazole on the skin and colon microflora in patients with rosacea. Infection. 1987;15:8-10.

24. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-50.

25. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40:961-5.

26. Elewski BE. Rosacea trial comparing twice-daily azelaic acid gel 15% with once-daily metronidazole gel 1%. Cutis. 2007;79:57-8.

27. Colón LE, Johnson LA, Gottschalk RW. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis. 2007;79:317-21.

28. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of oncedaily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(Suppl.4):3-11.

29. Nielsen PG. A double-blind study of I% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol. 1983;109:63-5.

30. Veien NK, Christiansen JV, Hjorth N, Schmidt H. Topical metronidazole in the treatment of rosacea. Cutis. 1986;38:209-10.

31. Torok HM, Webster G, Dunlap FE, Egan N, Jarratt M, Stewart D. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis. 2005;75:357-63.

32. Koçak M, Yağli S, Vahapoğlu G, Ek ioğlu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology (Basel). 2002;205:265-70.

33. Signore RJ. A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. Cutis. 1995;56:177-9.

34. Koca R, Altinyazar HC, Ankarali H, Muhtar S, Tekin NS, Cinar S. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: A randomized open-label clinical trial. Clin. Exp Dermatol. 2010;35:251-6.

35. Oztürkcan S, Ermertcan AT, Sahin MT, Af ar FS. Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. J Dermatol. 2004;31:610-7.

36. Altinyazar HC, Koca R, Tekin NS, E türk E. Adapalene Vs. metronidazole gel for the treatment of rosacea. Int J Dermatol. 2005;44:252-5.

37. Mostafa FF, El Harras MA, Gomaa SM, Al Mokadem S, Nassar AA, Abdel Gawad EH. Comparative study of some treatment modalities of rosacea. J Eur Acad Dermatol Venereol. 2009;23:22-8.

38. Del Rosso JQ, Bruce S, Jarratt M, Menter A, Staedtler G. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulo-pustular rosacea. J Drugs Dermatol. 2010;9:607-13.

39. Mayr-Kanhäuser S, Kränke B, Kaddu S, Müllegger RR. Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. Eur J Gastroenterol Hepatol. 2001;13:1379-83.

40. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40 mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641-5.

41. Sanchez J, Somolinos AL, Almodóvar PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20 mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53:791-7.

42. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol. 1980;102:443-5.

43. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-45.

44. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol. 1999;79:456-9.

45. Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulo-pustular rosacea. J Drugs Dermatol. 2008;7:541-6.

46. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8:639-48.

47. Draelos ZD, Green BA, Edison BL. An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients. J Cosmet Dermatol. 2006;5:23-9.

48. Del Rosso JQ, Webster GF, Jackson M, Rendon M, Rich P, Torok H, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40 mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-802.

49. Bartholomew RS, Reid BJ, Cheesbrough MJ, Macdonald M, Galloway NR. Oxytetracycline in the treatment of ocular rosacea: A double-blind trial. Br J Ophthalmol. 1982;66:386-8.

50. Määttä M, Kari O, Tervahartiala T, Peltonen S, Kari M, Saari M, et al. Tear fluid levels of MMP-8 are elevated in ocular rosacea- -treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol. 2006;244:957-62.

51. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of antiinflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7:573-6.

52. Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30 mg immediate-release and 10 mg delayedrelease beads). Cutis. 2010;86(Suppl.5):7-15.

53. Del Rosso JQ. Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: Results from a communitybased trial. Cutis. 2010;86(Suppl.%):16-25.

54. Quarterman MJ, Johnson DW, Abele DC, Lesher JL Jr, Hull DS, Davis LS. Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:49-54.

55. Ta CN, Shine WE, McCulley JP, Pandya A, Trattler W, Norbury JW. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea. 2003;22:545-8.

56. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin Vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47:284-8.

57. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 1997;36:942-6.

58. Wilkin JK, DeWitt S. Treatment of rosacea: Topical clindamycin versus oral tetracycline. Int J Dermatol. 1993;32:65-7.

59. Seal DV, Wright P, Ficker L, Hagan K, Troski M, Menday P. Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. Br J Ophthalmol. 1995;79:42-5.

60. Ranu H, Lee J, Hee TH. Therapeutic hotline: Successful treatment of Morbihan’s disease with oral prednisolone and doxycycline. Dermatol Ther. 2010;23:682-5.

61. Gollnick H, Blume-Peytavi U, Szabó EL, Meyer KG, Hauptmann P, Popp G, et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges. 2010;8:505-15.

62. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-24.

63. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol. 1986;25:660-3.

64. Marsden JR, Shuster S, Neugebauer M. Response of rosacea to isotretinoin. Clin Exp Dermatol. 1984;9:484-8.

65. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134:884-5.

66. Hofer T. Continuous «microdose» isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol. 2004;29:204-5.

67. Gajardo J. Severe rosacea treated with oral isotretinoin. Rev Med Chil. 1994;122:177-9.

68. Turjanmaa K, Reunala T. Isotretinoin treatment of rosacea. Acta Derm Venereol. 1987;67:89-91.

69. Lembo G, Giannetti A. Treatment of acne rosacea with 13-cisretinoic acid. Med Cutan Ibero Lat Am. 1987;15:274-6.

70. Schmidt JB, Gebhart W, Raff M, Spona J. 13-cis-retinoic acid in rosacea. Clinical and laboratory findings. Acta Derm. Venereol. 1984;64:15-21.

71. Bostanci O, Borelli C, Schaller M. Treatment of extrafacial rosacea with low-dose isotretinoin. Acta Derm Venereol. 2010;90:409-10.

72. Vienne MP, Ochando N, Borrel MT, Gall Y, Lauze C, Dupuy P. Retinaldehyde alleviates rosacea. Dermatology (Basel). 1999;199(Suppl.1):53-6.

73. Firooz A, Firoozabadi MR, Dowlati Y. Rosacea fulminans (pyoderma faciale): Successful treatment of a 3-year-old girl with oral isotretinoin. Int J Dermatol. 2001;40:203-5.

74. McHugh RC, Rice A, Sangha ND, McCarty MA, Utterback R, Rohrback JM, et al. A topical azithromycin preparation for the treatment of acne vulgaris and rosacea. J Dermatolog Treat. 2004;15:295-302.

75. Bakar O, Demirçay Z, Yuksel M, Haklar G, Sanisoglu Y. The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol. 2007;32:197-200.

76. Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol. 2009;23:544-9.

77. Fernandez-Obregon A, Patton DL. The role of Chlamydia pneumoniae in the etiology of acne rosacea: Response to the use of oral azithromycin. Cutis. 2007;79:163-7.

78. Elewski BE. A novel treatment for acne vulgaris and rosacea. J Eur Acad Dermatol Venereol. 2000;14:423-4.

79. Fernandez-Obregon A. Oral use of azithromycin for the treatment of acne rosacea. Arch Dermatol. 2004;140:489-90.

80. Bakar O, Demirçay Z, Gürbüz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43:151-4.

81. Modi S, Harting M, Rosen T. Azithromycin as an alternative rosacea therapy when tetracyclines prove problematic. J Drugs Dermatol. 2008;7:898-9.

82. Sehgal VN, Sharma S, Sardana K. Rosacea/acne rosacea: Efficacy of combination therapy of azithromycin and topical 0.1% tacrolimus ointment. J Eur Acad Dermatol Venereol. 2008;22:1366-8.

83. Fuentelsaz V, Ara M, Corredera C, Lezcano V, Juberias P, Carapeto FJ. Rosacea fulminans in pregnancy: Successful treatment with azithromycin. Clin Exp Dermatol. 2011;36:674-6.

84. Karabulut AA, Izol Serel B, Eksioglu HM. A randomized, singleblind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulo-pustular rosacea. J Eur Acad Dermatol Venereol. 2008;22:729-34.

85. Weissenbacher S, Merkl J, Hildebrandt B, Wollenberg A, Braeutigam M, Ring J, et al. Pimecrolimus cream 1% for papulopustular rosacea: A randomized vehicle-controlled double-blind trial. Br J Dermatol. 2007;156:728-32.

86. Lee DH, Li K, Suh DH. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: An 8-week split-face clinical trial. Br J Dermatol. 2008;158:1069-76. 87. Chu C-Y. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol. 2005;152:396-9.

88. Chu C-Y. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption. J Eur Acad Dermatol Venereol. 2007;21:484-90.

89. Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed. 2005;4:147-50.

90. Cunha PR, Rossi AB. Pimecrolimus cream 1% is effective in a case of granulomatous rosacea. Acta Derm Venereol. 2006;86:71-2.

91. Gül U, Gönül M, Kiliç A, Koçak O, Aslan E, Ergül G, et al. A case of granulomatous rosacea successfully treated with pimecrolimus cream. J Dermatolog Treat. 2008;19:313-5.

92. Bamford JTM, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol. 2004;50:107-8.

93. Goldman D. Tacrolimus ointment for the treatment of steroidinduced rosacea: A preliminary report. J Am Acad Dermatol. 2001;44:995-8.

94. Antille C, Saurat J-H, Lübbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004;140:457-60.

95. Lübbe J, Milingou M. Images in clinical medicine. Tacrolimus ointment, alcohol, and facial flushing. N Engl J Med. 2004;351:2740.

96. Milingou M, Antille C, Sorg O, Saurat J-H, Lübbe J. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol. 2004;140:1542-4.

97. Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea. J Eur Acad Dermatol Venereol. 2009;23:239-40.

98. Bamford JT, Tilden RL, Blankush JL, Gangeness DE. Effect of treatment of Helicobacter pylori infection on rosacea. Arch Dermatol. 1999;135:659-63.

99. Gedik GK, Karaduman A, Sivri B, Caner B. Has Helicobacter pylori eradication therapy any effect on severity of rosacea symptoms? J Eur Acad Dermatol Venereol. 2005;19:398-9.

100. Uta S, Ozbakir O, Turasan A, Uta C. Helicobacter pylori eradication treatment reduces the severity of rosacea. J Am Acad Dermatol. 1999;40:433-5.

101. Son SW, Kim IH, Oh CH, Kim JG. The response of rosacea to eradication of Helicobacter pylori. Br J Dermatol. 1999;140:984-5.

102. Boixeda de Miquel D, Vázquez Romero M, Vázquez Sequeiros E, Foruny Olcina JR, Boixeda de Miquel P, López San Román A, et al. Effect of Helicobacter pylori eradication therapy in rosacea patients. Rev Esp Enferm Dig. 2006;98:501-9.

103. Parodi A, Paolino S, Greco A, Drago F, Mansi C, Rebora A, et al. Small intestinal bacterial overgrowth in rosacea: Clinical effectiveness of its eradication. Clin. Gastroenterol Hepatol. 2008;6:759-64.

104. Candelli M, Carloni E, Nista EC, Cazzato IA, Pignataro G, Rigante D, et al. Helicobacter pylori eradication and acne rosacea resolution: cause-effect or coincidence? Dig Liver Dis. 2004;36:163.

105. Dakovi Z, Vesi S, Vukovi J, Milenkovi S, Jankovi-Terzi K, Duki S, et al. Ocular rosacea and treatment of symptomatic Helicobacter pylori infection: A case series. Acta Dermatovenerol Alp Panonica Adriat. 2007;16:83-6.

106. Mayr-Kanhäuser S, Kränke B, Kaddu S, Müllegger RR. Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. Eur J Gastroenterol Hepatol. 2001;13:1379-83.

107. Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol. 2009;8:299-304.

108. Draelos ZD. The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses. J Drugs Dermatol. 2010;9:234-6.

109. Allen KJ, Davis CL, Billings SD, Mousdicas N. Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin. Cutis. 2007;80:149-51.

110. Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41:775-7.

111. Montes LF, Cordero AA, Kriner J, Loder J, Flanagan AD. Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis. 1983;32:185-90.

112. Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43:381-7.

113. Leyden JJ, Thiboutot D, Shalita A. Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis. 2004;73(Suppl.6):11-7.

114. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol. 1989;20:202-5.

115. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26:651-9.

116. Mills OH Jr, Kligman AM. Topically applied erythromycin in rosacea. Arch Dermatol. 1976;112:553-4.

117. Sharquie KE, Najim RA, Al-Salman HN. Oral zinc sulfate in the treatment of rosacea: A double-blind, placebo-controlled study. Int J Dermatol. 2006;45:857-61.

118. Rigopoulos D, Kalogeromitros D, Gregoriou S, Pacouret JM, Koch C, Fisher N, et al. Randomized placebo-controlled trial of a flavonoid-rich plant extract-based cream in the treatment of rosacea. J Eur Acad Dermatol Venereol. 2005;19:564-8.

119. Auada-Souto MP, Velho PE. Low-strength trichloroacetic acid in the treatment of rosacea. J Eur Acad Dermatol Venereol. 2007;21:1443-5.

120. Bormann G, Gaber G, Fischer M, Marsch WC. Dapsone in rosacea fulminans. J Eur Acad Dermatol Venereol. 2001;15:465-7.

121. Laquieze S, Czernielewski J, Baltas E. Beneficial use of cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. J Dermatolog Treat. 2007;18:158-62.

122. Draelos ZD, Fuller BB. Efficacy of 1% 4-ethoxybenzaldehyde in reducing facial erythema. Dermatol Surg. 2005;31:881-5. 123. Ortiz A, Elkeeb L, Truitt A, Hindiyeh R, Aquino L, Tran M, et al. Topical PRK 124 (0.125%) lotion for improving the signs and symptoms of rosacea. J Drugs Dermatol. 2009;8:459-62.

124. Tremaine AM, Ortiz A, Elkeeb L, Tran M, Weinstein G. Long-term efficacy and safety of topical PRK 124 (0.125%) lotion (PyratineXR) in the treatment of mild-to-moderate rosacea. J Drugs Dermatol. 2010;9:647-50.

125. Wollina U. The response of erythematous rosacea to ondansetron. Br J Dermatol. 1999;140:561-2.

126. Weber TM, Ceilley RI, Buerger A, Kolbe L, Trookman NS, Rizer RL, et al. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing licochalcone A. J Cosmet Dermatol. 2006;5:227-32.

127. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(Suppl.1):26-34.

128. Wozniacka A, Wieczorkowska M, Gebicki J, Sysa-Jedrzejowska A. Topical application of 1-methylnicotinamide in the treatment of rosacea: A pilot study. Clin Exp Dermatol. 2005;30:632-5.

129. Berardesca E, Cameli N, Cavallotti C, Levy JL, Piérard GE, de Paoli Ambrosi G. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: Clinical and instrumental evaluation. J Cosmet Dermatol. 2008;7:8-14.

130. Wu JJ, Weinstein GD, Kricorian GJ, Kormeili T, McCullough JL. Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea. Clin Exp Dermatol. 2007;32:693-5.

131. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1- adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143:1369-71.

132. Hsu C-C, Lee JY-Y. Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea. Arch Dermatol. 2011;147:1258-60.

133. Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol. 2005;53:881-4.

134. Aizawa H, Niimura M. Oral spironolactone therapy in male patients with rosacea. J Dermatol. 1992;19:293-7.

135. Bernstein JE, Soltani K. Alcohol-induced rosacea flushing blocked by naloxone. Br J Dermatol. 1982;107:59-61.

136. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol. 1983;119:211-4.

137. Ruiz-Esparza J, Barba Gomez JM, Rosales Berber I. A possible role for non-ablative radiofrequency in the treatment of rosacea. J Drugs Dermatol. 2003;2:621-3.

138. Mark KA, Sparacio RM, Voigt A, Marenus K, Sarnoff DS. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg. 2003;29:600-4.

139. Papageorgiou P, Clayton W, Norwood S, Chopra S, Rustin M. Treatment of rosacea with intense pulsed light: Significant improvement and long-lasting results. Br J Dermatol. 2008;159:628-32.

140. Schroeter CA, Haaf-von Below S, Neumann HAM. Effective treatment of rosacea using intense pulsed light systems. Dermatol Surg. 2005;31:1285-9.

141. Taub AF. Treatment of rosacea with intense pulsed light. J Drugs Dermatol. 2003;2:254-9.

142. Lane JE, Khachemoune A. Use of intense pulsed light to treat refractory granulomatous rosacea. Dermatol Surg. 2010;36:571-3.

143. Jasim ZF, Woo WK, Handley JM. Long-pulsed (6-ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold. Dermatol Surg. 2004;30:37-40.

144. Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol. 2004;51:592-9.

145. Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythemato-telangiectatic rosacea. Dermatol Surg. 2009;35:920-8.

146. Kim TG, Roh HJ, Cho SB, Lee JH, Lee SJ, Oh SH. Enhancing effect of pretreatment with topical niacin in the treatment of rosacea-associated erythema by 585-nm pulsed dye laser in Koreans: A randomized, prospective, split-face trial. Br J Dermatol. 2011;164:573-9.

147. Togsverd-Bo K, Wiegell SR, Wulf HC, Haedersdal M. Short and limited effect of long-pulsed dye laser alone and in combination with photodynamic therapy for inflammatory rosacea. J Eur Acad Dermatol Venereol. 2009;23:200-1.

148. Larson AA, Goldman MP. Recalcitrant rosacea successfully treated with multiplexed pulsed dye laser. J Drugs Dermatol. 2007;6:843-5.

149. Miller A. Treatment of erythematotelangiectactic rosacea with a KTP YAG laser. J Drugs Dermatol. 2005;4:760-2.

150. Maxwell EL, Ellis DAF, Manis H. Acne rosacea: Effectiveness of 532 nm laser on the cosmetic appearance of the skin. J Otolaryngol Head Neck Surg. 2010;39:292-6.

151. Nybaek H, Jemec GBE. Photodynamic therapy in the treatment of rosacea. Dermatology (Basel). 2005;211:135-8.

152. Bryld LE, Jemec GBE. Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venereol. 2007;21:1199-202.

153. Katz B, Patel V. Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea. J Drugs Dermatol. 2006;5(Suppl.2):6-8.

154. Ersek RA, Denton DR. Rhinophyma: Treatment with electrocautery and silver-impregnated porcine xenograft. Plast Reconstr Surg. 1984;74:269-73.

155. Humzah MD, Pandya AN. A modified electroshave technique for the treatment of rhinophyma. Br J Plast Surg. 2001;54:322-5.

156. Bogetti P, Boltri M, Spagnoli G, Dolcet M. Surgical treatment of rhinophyma: a comparison of techniques. Aesthetic Plast Surg. 2002;26:57-60.

157. Köse R, Okur MI, Güldür ME. Giant rhinophyma in a bronchial asthma patient treated by excision and full thickness skin grafting. Dermatol. Online J. 2008;14:9.

158. Schintler MV, Arbab E, Aberer W, Spendel S, Scharnagl E. Surgical management of extensive gnathophyma. J Eur Acad Dermatol Venereol. 2006;20:1325-7.

159. Stucker FJ, Lian T, Sanders K. The ABCs of rhinophyma management. Am J Rhinol. 2003;17:45-9.

160. Redett RJ, Manson PN, Goldberg N, Girotto J, Spence RJ. Methods and results of rhinophyma treatment. Plast Reconstr Surg. 2001;107:1115-23.

161. Gupta S, Handa S, Saraswat A, Kumar B. Conventional cold excision combined with dermabrasion for rhinophyma. J Dermatol. 2000;27:116-20.

162. Taghizadeh R, Mackay SP, Gilbert PM. Treatment of rhinophyma with the Versajet Hydrosurgery System. J Plast Reconstr Aesthet Surg. 2008;61:330-3.

163. Dufresne RG, Zienowicz RJ, Rozelle A, Whalen JD. An introduction of the ultrasonic scalpel: Utility in treatment of rhinophyma. Plast Reconstr Surg. 1996;98:160-2.

164. Tenna S, Gigliofiorito P, Langella M, Carusi C, Persichetti P. Treatment of rhinophyma with ultrasonic scalpel: Case report. J Plast Reconstr Aesthet Surg. 2009;62:e164-5.

165. Vural E, Royer MC, Kokoska MS. Sculpting resection of rhinophyma using the Shaw scalpel. Arch Facial Plast Surg. 2009;11:263-6.

166. Eisen RF, Katz AE, Bohigian RK, Grande DJ. Surgical treatment of rhinophyma with the Shaw scalpel. Arch Dermatol. 1986;122:307-9.

167. Seiverling EV, Neuhaus IM. Nare obstruction due to massive rhinophyma treated using the Shaw scalpel. Dermatol Surg. 2011;37:876-9.

168. Karim Ali M, Streitmann MJ. Excision of rhinophyma with the carbon dioxide laser: A ten-year experience. Ann Otol Rhinol Laryngol. 1997;106:952-5.

169. Madan V, Ferguson JE, August PJ. Carbon dioxide laser treatment of rhinophyma: A review of 124 patients. Br J Dermatol. 2009;161:814-8.

170. Lim S-W, Lim S-W, Bekhor P. Rhinophyma: Carbon dioxide laser with computerized scanner is still an outstanding treatment. Australas J Dermatol. 2009;50:289-93.

171. Skoulakis CE, Papadakis CE, Papadakis DG, Bizakis JG, Kyrmizakis DE, Helidonis ES. Excision of rhinophyma with a laser scanner handpiece--a modified technique. Rhinology. 2002;40:83-7.

172. Hsu C-K, Lee JY-Y, Wong T-W. Good cosmesis of a large rhinophyma after carbon dioxide laser treatment. J Dermatol. 2006;33:227-9.

173. Jovanovic S, Sedlmaier B. CO2 laser therapy for rhinophyma. Facial Plast Surg. 1998;14:279-86.

174. Simo R, Sharma VL. The use of the CO2 laser in rhinophyma surgery: Personal technique and experience, complications, and long-term results. Facial Plast Surg. 1998;14:287-95.

175. Lomeo P, McDonald J, Finneman J. Rhinophyma: treatment with CO2 laser. Ear Nose Throat J. 1997;76:740-3.

176. Lloyd KM. Surgical correction of rhinophyma. Arch Dermatol. 1990;126:721-3.

177. Lomeo PE, McDonald JE, Finneman J. Obstructing rhinophyma: A case report. Otolaryngol Head Neck Surg. 2005;133:799-800.

178. Goon PKY, Dalal M, Peart FC. The gold standard for decortication of rhinophyma: Combined erbium-YAG/ CO2 laser. Aesthetic Plast Surg. 2004;28:456-60.

179. Cravo M, Miguel Canelas M, Carlos Cardoso J, Vieira R, Figueiredo A. Combined carbon dioxide laser and bipolar electrocoagulation: Another option to treat rhinophyma. J Dermatolog Treat. 2009;20:146-8.

180. Vojinovi M, Bili M, Kovac L, Persi-Vojinovi S, Basta-Juzbasi A. Treatment of massive rhinophyma by combined electrosurgery and CO2 laser. Acta Dermatovenerol Croat. 2009;17:20-4.

181. Moreira A, Leite I, Guedes R, Baptista A, Mota G. Surgical treatment of rhinophyma using carbon dioxide (CO2 ) laser and pulsed dye laser (PDL). J Cosmet Laser Ther. 2010;12:73-6.

182. Greenbaum SS, Krull EA, Watnick K. Comparison of CO2 laser and electrosurgery in the treatment of rhinophyma. J Am Acad Dermatol. 1988;18:363-8.

183. Roje Z, Racic G. Management of rhinophyma with coblation. Dermatol Surg. 2010;36:2057-60.

184. Hetherington HE. Coblation-assisted decortication for the treatment of rhinophyma. Laryngoscope. 2009;119:1082-4.

185. Timms M, Roper A, Patrick C. Coblation of rhinophyma. J Laryngol Otol. 2011;125:724-8.

186. Erisir F, Isildak H, Haciyev Y. Management of mild to moderate rhinophyma with a radiofrequency. J Craniofac Surg. 2009;20:455-6.

187. Tahery J, Zakaria R, Natt RS. Diode laser treatment of rhinophyma. Clin Otolaryngol. 2010;35:442-4.

188. Apikian M, Goodman GJ, Roberts S. Management of mild to moderate rhinophyma with a 1,450-nm diode laser: Report of five patients. Dermatol Surg. 2007;33:847-50.

189. Orenstein A, Haik J, Tamir J, Winkler E, Frand J, Zilinsky I, et al. Treatment of rhinophyma with Er:YAG laser. Lasers Surg Med. 2001;29:230-5.

190. Fincher EF, Gladstone HB. Use of a dual-mode erbium: YAG laser for the surgical correction of rhinophyma. Arch Facial Plast Surg. 2004;6:267-71.

191. Wenig BL, Weingarten RT. Excision of rhinophyma with Nd:YAG laser: A new technique. Laryngoscope. 1993;103:101-3.

192. Skala M, Delaney G, Towell V, Vladica N. Rhinophyma treated with kilovoltage photons. Australas. J Dermatol. 2005;46:88-9.

193. Plenk HP. Rhinophyma, associated with carcinoma, treated successfully with radiation. Plast Reconstr Surg. 1995;95:559-62.

194. González JA, Boixeda P, Díez MTT, Markixana IA, Jaén P. Cystic lesions associated with rhinophyma treated with an ablative fractional yttrium-scandium-gallium-garnet laser. J Cosmet Laser Ther. 2010;12:261-3.
Cómo citar
1.
Molina AL, Londoño Ángela, Escobar SM, Benítez M. Guías clínicas para el tratamiento de la rosácea. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 1 de diciembre de 2012 [citado 27 de noviembre de 2022];20(4):339-64. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/996

Descargas

Los datos de descargas todavía no están disponibles.
Publicado
2012-12-01
Sección
Artículo de revisión